A phase 2a randomised, double-blind, placebo-controlled, parallel-group, add-on clinical trial of ebselen (SPI-1005) as a novel treatment for mania or hypomania.

Psychopharmacology (Berl) · 2020 · PMC7683468 · PMID 32909076

Europe PMC DOI

hedged sentence

0.0540

closest p · 1.1× alpha

0.0540

boldest claim

The sentences

of borderline significancep = 0.054so close (0.05 < p ≤ 0.1)

An improvement in YMRS scores in the ebselen group, of borderline significance, was seen at 3 weeks (adjusted means and 95% CI, − 3.67 (− 7.39 to 0.06), p = 0.054) (Fig. 3 ).

also in 2,624 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.